Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 13 November 2019. Ted Tanner.

Executive Summary

Ted Tanner, CTO of IBM Watson Health, recently sat down with Medtech Insight to talk about his plans for developing a blockchain-based data information exchange network in partnership with health organizations to create 'frictionless' computing. See what Tanner said about it here.

You may also be interested in...



Exec Chat: XMed2019: How IBM Watson Health's CTO Uses Blockchain To Eliminate 'Friction Points' In Health Care

Ted Tanner, the new chief technology officer and chief architect of IBM Watson Health, recently sat down with Medtech Insight to discuss his plans for the company. In 2020, IBM will start testing the first use cases of its blockchain-based data information exchange network, a partnership with several health-care organizations, aimed at reducing administrative errors and costs. Tanner refers to blockchain as an "enablement platform" that augments computing power.

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

Topics

UsernamePublicRestriction

Register

MT125895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel